On November 29, 2021 ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, reported that it has signed a 2-year collaboration agreement with Imperial College London (Press release, ImmuPharma, NOV 29, 2021, View Source [SID1234596195]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the collaboration, Imperial College will provide significant intellectual input and guidance on a number of innovative peptide assets being developed at our R&D subsidiary, ImmuPharma Biotech in Bordeaux.

Dr Tim Franklin, Chief Operating Officer of ImmuPharma, added: "We are all extremely excited to be working with such a world leading academic institute. This union will be invaluable in guiding and progressing our earlier stage product development portfolio, as well as enhancing our intellectual property base."

Dr Sébastien Goudreau, Chief Executive Officer of ImmuPharma Biotech, added: "We are delighted that now with the full support from the new Board for our innovative research programs, we have the opportunity of working with collaboration partners which include world leading academic institutes such as Imperial College London."